Semaglutide’s Potential Beneficial Effects on Heart Failure with Preserved Ejection Fraction in Obese Patients Studied.

https://pubmed.ncbi.nlm.nih.gov/38118036

The abstract is about a clinical study investigating the effects of semaglutide, a glucagon-like peptide-1 receptor agonist, on heart failure with preserved ejection fraction in patients with obesity.

In one sentence: This study suggests that semaglutide may have beneficial effects on heart failure with preserved ejection fraction in patients with obesity.